An observational study in Retinal Dystrophies, sponsored by Institute of Molecular and Clinical Ophthalmology Basel. Recruiting at 9 sites in 7 countries. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Institute of Molecular and Clinical Ophthalmology Basel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.
Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 11th registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
University of Rochester · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8
First in 1994; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 112 across 26 observational studies indexed under Retinal Dystrophies.
Median enrollment 20 across the 16 interventional studies, 35 across the 11 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 27 have an industry lead sponsor. The 10 most frequent:
Institute of Molecular and Clinical Ophthalmology Basel is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Institute of Molecular and Clinical Ophthalmology Basel has 1 study filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
8 of the studies in Retinal Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT05626920University of WashingtonDisulfiram for Treatment of Retinal Degeneration | 2027-02-01 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 27 studies in Retinal Dystrophies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.
Inclusion Criteria (patients):
Inclusion Criteria (controls):
Exclusion Criteria (all):
-Availability of macular optical coherence tomography (OCT)
Diagnostic Test: Optical coherence tomography (OCT)
-Availability of macular optical coherence tomography (OCT)
Diagnostic Test: Optical coherence tomography (OCT)
Data of macular optical coherence tomography (OCT)
OCT - Central retinal volume
Number of participants with preserved central retinal volume
Time frame: Baseline (about 10 minutes)
Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Molecular and Clinical Ophthalmology Basel